Beverly Hills Cancer Center

Beverly Hills, CA
(888) 828-2206

Accepting patients

MagnetisMM-32

Phase 3 Clinical Trial Comparing the Safety and Effectiveness of Elranatamab Versus Commonly Used Combination Regimens in Participants with Relapsed/Refractory Multiple Myeloma
Learn more
  • Bispecific Antibody
  • BCMA
  • Phase 3

Accepting patients

MagnetisMM-20

Phase 1B Study Evaluating Elranatamab in Combination with Carfilzomib/Dexamethasone or in Combination with PF-07901801 (maplirpacept) in Relapsed/Refractory Multiple Myeloma
Learn more
  • Bispecific Antibody
  • BCMA
  • Phase 1
Get personalized results in 60 seconds
All clinical trials have eligibility criteria - or a list of reasons why you may be able or unable to participate in a trial. Answer a few questions to view your personalized results - all in under 60 seconds.
Help me find trials

Accepting patients

MagnetisMM-4

Phase 1/2 Clinical Trial Evaluating the Safety, Effectiveness and Best Dose of Elranatamab Combined with Different Anti-Cancer Therapies in Participants with Multiple Myeloma
Learn more
  • Bispecific Antibody
  • Gamma-Secretase Inhibitor
  • BCMA
  • Phase 1/2

Accepting patients

DREAMM13

A Phase I Study of Belantamab Mafodotin in Multiple Myeloma Participants with Normal and Impaired Hepatic Function
Learn more
  • Antibody Drug Conjugate (ADC)
  • BCMA
  • Phase 1

Accepting patients

DREAMM12

A Study of Belantamab Mafodotin (GSK2857916) in Multiple Myeloma Participants With Normal and Varying Degrees of Impaired Renal Function
Learn more
  • Antibody Drug Conjugate (ADC)
  • BCMA
  • Phase 1